Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Domvanalimab - Arcus Biosciences

Next Previous
Drug Profile

Domvanalimab - Arcus Biosciences

Alternative Names: AB 154; GS-0154

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abmuno Therapeutics
  • Developer Arcus Biosciences; AstraZeneca; Gilead Sciences; University of Texas Southwestern Medical Center; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastrointestinal cancer; Non-small cell lung cancer
  • Phase II Liver cancer
  • Phase I/II Cancer; Pancreatic cancer
  • Phase I Glioblastoma

Most Recent Events

  • 16 Apr 2024 Arcus Biosciences and Gilead plans a phase III STAR-131 trial for Non small cell lung cancer
  • 29 Jan 2024 Arcus Biosciences plans a phase III trial in Non-small cell lung cancer in the US, Hong Kong, Malaysia, Philippines, Slovakia, South Africa, Thailand, Vietnam, Spain, Greece, and Ireland (IV) (NCT04736173)
  • 29 Jan 2024 Arcus Biosciences terminates a phase III trial for Non-small cell lung cancer in the US, Hong Kong, Malaysia, Philippines, Slovakia, South Africa, Thailand, Vietnam, Spain, Greece, and Ireland (IV) based on strategic prioritization to advance and potentially accelerate the Phase 3 studies STAR-121 and STAR-221 (NCT04736173)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top